Idraparinux and idrabiotaparinux

References

• Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest133(6 Suppl.), 454S–545S (2008).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest133(6 Suppl.), 340S–380S (2008).
   PubMedGoogle Scholar
• Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest133, 160S–198S (2008).
   PubMed Web of Science ®Google Scholar
• Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest133(6 Suppl.), 546S––592S (2008).
   PubMed Web of Science ®Google Scholar
• Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest133(6 Suppl.), 141S–159S (2008).
   PubMedGoogle Scholar
• Koopman MMW, Büller HR. Short- and long-acting synthetic pentasaccharides. J. Intern. Med.254, 335–342 (2003).
   PubMed Web of Science ®Google Scholar
• Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest133(6 Suppl.), 234S–256S (2008).
   PubMedGoogle Scholar
• Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin. Thromb. Hemost.34, 39–57 (2008).
   PubMed Web of Science ®Google Scholar
• Prandoni P, Tormene D, Perlati M, Brandolin B, Spiezia L. Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders. Expert Opin. Investig. Drugs17, 773–777 (2008).
   PubMed Web of Science ®Google Scholar
• Herbert JM, Hérault JP, Bernat A et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood91, 4197–4205 (1998).
   PubMed Web of Science ®Google Scholar
• Organon, Sanofi-Synthelabo. Idraparinux sodium. Drug Data Rep.25, 332 (2003).
   Google Scholar
• Van Amsterdam RGM, Burggraaf J, Borm GF et al. A Phase I multiple dose study to investigate the safety, tolerance and pharmacokinetics of 10 mg SC SanOrg34006 in male and female volunteers with a history of VTE, recently discharged from oral anticoagulant treatment. Clinical Trial Report on Protocol 64703. NV Organon. R&DRR NL0028967.
   Google Scholar
• Faaij RA, Burggraaf J, Schoemaker RC et al. A Phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of subcutaneous SANORG 34006 in healthy male and female elderly volunteers. Thromb. Haemost. (Suppl.), (1999) (Abstract 1547).
   Google Scholar
• Faaij RA, Burggraaf J, Schoemaker RC, et al. A Phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of SANORG 34006 in healthy young male volunteers. Thromb. Haemost. (Suppl.), (1999) (Abstract 2709).
   Google Scholar
• Idraparinux sodium. Drug Data Rep.25(4), 332 (2003).
   Google Scholar
• PERSIST investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J. Thromb. Haemost.2, 47–53 (2004).
   PubMed Web of Science ®Google Scholar
• Harenberg J, Jörg I, Vukojevic Y, Mikus G, Weiss C. Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. Eur. J. Clin. Pharmacol.64, 555–563 (2008).
   PubMed Web of Science ®Google Scholar
• Veyrat-Follet C, Vivier N, Trellu M, Dubruc C, Sanderink GJ. The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. J. Thromb. Haemost.7, 559–565 (2009).
   PubMed Web of Science ®Google Scholar
• Ma Q, Fareed J. Idraparinux sodium. Sanofi-Aventis. IDrugs7(11), 1028–1034 (2004).
   PubMed Web of Science ®Google Scholar
• Bijsterveld NR, Vink R, Van Arken BE et al. Recombinant factor VIIa reverses the anticoagulant effect of the longacting pentasaccharide idraparinux in healthy volunteers. Br. J. Haematol.124, 653–658 (2004).
   PubMed Web of Science ®Google Scholar
• The van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. N. Engl. J. Med.357, 1094–1104 (2007).
   PubMed Web of Science ®Google Scholar
• The van Gogh Investigators. Extended prophylaxis of venous thromboembolism with idraparinux. N. Engl. J. Med.357, 1105–1112 (2007).
   PubMed Web of Science ®Google Scholar
• Harenberg J, Weiss C, Mikus G, Joerg I, Vukojevic Y. Long elimination half life of idraparinux after termination of therapy explains bleeding in the van Gogh trials. J. Thromb. Haemost.6, 890–892 (2008).
   PubMed Web of Science ®Google Scholar
• Hjelm R, Schedin-Weiss S. High affinity interaction between a synthetic, highly negatively charged pentasaccharide and α- or β-antithrombin is predominantly due to nonionic interactions. Biochemistry46, 3378–3384 (2007).
   PubMed Web of Science ®Google Scholar
• The AMADEUS Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomized, open-label, non-inferiority trial. Lancet371, 315–321 (2008).
   PubMed Web of Science ®Google Scholar
• Benatar J, Stewart RA. Cutaneous blood-filled vesicles on idraparinux. Lancet372, 1949 (2008).
   PubMedGoogle Scholar
• Kang YS, Saito Y, Pardridge WM. Pharmacokinetics of [3H]biotin bound to different avidin analogues. J. Drug Target3, 159–165 (1995).
   PubMed Web of Science ®Google Scholar
• Wilchek M, Bayer EA. The avidin–biotin complex in bioanalytical applications. Anal. Biochem.171, 1–32 (1988).
   PubMed Web of Science ®Google Scholar
• Muus CJ, Azar HA. Application of immunochemistry to the diagnosis of human neoplasms in routine histologic sections. Diagn. Immunol.4, 125–139 (1986).
   PubMedGoogle Scholar
• Huntington JA, McCoy A, Belzar KJ, Pei XY, Gettins PG, Carrell RW. The conformational activation of antithrombin. A 2.85-A structure of a fluorescein derivative reveals an electrostatic link between the hinge and heparin binding regions. J. Biol. Chem.275, 15377–15383 (2000).
   PubMed Web of Science ®Google Scholar
• Savi P, Herault JP, Duchaussoy P et al. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J. Thromb. Haemost.6, 1697–1706 (2008).
   PubMed Web of Science ®Google Scholar
• Burkhart KK, Britt AM. Reversal of toxicity using avidin-based hemoperfusion: a model system in rats using biotinylated melittin. Pharmacology50, 307–312 (1995).
   PubMed Web of Science ®Google Scholar
• Stoldt HS, Aftab F, Chinol M et al. Pretargeting strategies for radio-immunoguided tumour localisation and therapy. Eur. J. Cancer33, 186–192 (1997).
   PubMed Web of Science ®Google Scholar
• Trellu M, Perez Y, Ortiz J, Cheng S, Paty I. Bioequipotency of idraparinux and biotinylated idraparinux after single dose in healthy subjects. J. Thromb. Haemost.5(Suppl. 2), PT678 (2007).
   Google Scholar
• Buller HR, Destors JM, Gallus AS, Prins MH, Edward Raskob GE. Idrabiotaparinux, a biotinylated long-acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX study): safety, efficacy, and reversibility by avidin. Blood112, 18 (2008).
   Google Scholar
• Turpie AG. Fondaparinux: a factor Xa inhibitor for antithrombotic therapy. Expert Opin. Pharmacother.5, 1373–1384 (2004).
   PubMed Web of Science ®Google Scholar
• de Kort M, Buijsman RC, van Boeckel CA. Synthetic heparin derivatives as new anticoagulant drugs. Drug. Discov. Today10, 769–779 (2005).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Salim Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med.361, 1–13 (2009).
   PubMed Web of Science ®Google Scholar